Clinical Department of Rheumatology and Immunology, Medical University of Graz, Graz, Austria.
Centre for Epidemiology Versus Arthritis, Division of Musculoskeletal and Dermatological Science, School of Biological Sciences, Faculty of Biology Medicine and Health, The University of Manchester, Manchester, United Kingdom.
Best Pract Res Clin Rheumatol. 2023 Sep;37(3):101857. doi: 10.1016/j.berh.2023.101857. Epub 2023 Aug 3.
Comorbidities, including cardiovascular disease, osteoporosis, and depression, are more prevalent in patients with spondyloarthritis (SpA) than in the general population. Clinical and laboratory markers of disease activity are associated with numerous of these comorbidities, and studies suggest that the treatment of SpA can have a positive impact on comorbidities; conversely, managing comorbidities can improve disease activity. Therefore, the screening of comorbidities is considered a core component of a rheumatology consultation, and treatment should be performed in liaison with other health professionals (e.g. general physicians). Validated tools and questionnaires can be used for not only the detection but also the monitoring of potential comorbidities. Understanding whether a comorbidity is a separate disease entity, linked to SpA or its treatment, or an extra-musculoskeletal manifestation of the disease is important to identify the most appropriate treatment options.
合并症，包括心血管疾病、骨质疏松症和抑郁症，在患有脊柱关节炎（SpA）的患者中比在普通人群中更为普遍。疾病活动的临床和实验室标志物与许多这些合并症相关，并且研究表明 SpA 的治疗可以对合并症产生积极影响；相反，管理合并症可以改善疾病活动。因此，合并症的筛查被认为是风湿病咨询的核心组成部分，并且应该与其他健康专业人员（例如普通医生）一起进行治疗。验证过的工具和问卷不仅可用于检测，还可用于监测潜在的合并症。了解合并症是一种独立的疾病实体，与 SpA 或其治疗相关，还是疾病的肌肉骨骼外表现，对于确定最合适的治疗方案很重要。
